News | June 20, 2012

SNM's Position on Dose Optimization

June 20, 2012 — In nuclear medicine and molecular imaging, small amounts of radioactive agents are administered to the patient to allow the physician to examine molecular processes within the body. These procedures are highly effective, safe and painless diagnostic tools that present physicians with a detailed view of what’s going on inside an individual’s body at the cellular level. For more than 60 years, these studies have been used to evaluate practically all systems within the body, including the heart and brain, as well as to image many types of cancer.

The Society of Nuclear Medicine (SNM) and the SNM Technologist Section (SNMTS) recognize that the use of low levels of radiation in these procedures entails some possible risk. Radiation dose for all nuclear medicine and molecular imaging procedures should be optimized so that the patient receives the smallest possible amount of radiopharmaceutical that will provide the appropriate diagnostic information. SNM and SNMTS also recognize that if an appropriate procedure—one that can provide the physician with clinical information essential to the patient’s treatment—is not performed when necessary due to fear of radiation, it can be detrimental to the patient.

The SNM and SNMTS believe that the right test with the right dose should be given to the right patient at the right time. When nuclear medicine and molecular imaging procedures are performed correctly on appropriate patients, the benefits of the procedure far outweigh the potential risks. The procedure that provides the most useful clinical information is the one that should be performed.

To ensure the appropriate use of these procedures, all nuclear medicine facilities should have comprehensive quality control measures in place, their nuclear medicine physicians should have up-to-date training, and their technologists should be appropriately trained and certified. SNM and SNMTS and their members continually strive to improve quality and standards to ensure patients receive the best, safest and most appropriate care.

For more information: www.snm.org

 

 

Related Content

Lexington Begins HeartSentry Clinical Trial
News | Clinical Study | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Clinical Study | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Clinical Study | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Clinical Study | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init